ClinicalTrials.gg
RecruitingNCT06010901Updated Jan 23, 2024

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

A Phase 1 interventional study of TQB2618 injection and Penpulimab injection in Colorectal Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited — 6 open to participants now, 7 under way, 2 of them phase 3. Colorectal Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
6th of 13
75 · median 72
Started
2024
the only one that year
Phase 1
4 of 13
2 open now
Registered
8th of 13
by date

Among the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, this one is the 6th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 1, and was the 8th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection as monotherapy and a combination regimen (with Penpulimab injection ± Anlotinib hydrochloride capsules) in the treatment of advanced colorectal cancer. 75 participants will be enrolled in the study. Objective response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 is the primary endpoint.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-75 years old; Performance Status (ECOG PS) score: 0-1; Expected survival of more than 3 months;
  • Histologically/ confirmed colorectal cancer;
  • The subjects should provide tumor tissues that meet the requirements for mismatch repair protein detection and Programmed cell death-Ligand 1 () expression level detection;
  • Advanced colorectal cancer that progresses or is intolerant after receiving ≥3 lines of standard therapy;
  • Failure of treatment with at least one of these drugs (TAS-102, Regorafenib, Fruquintinib);
  • Confirmed presence of at least one according to 1.1 (RECIST 1.1) criteria;
  • Body weight ≥40 kg and (BMI) ≥18.5 kg/m\^2.
  • The function of the main organs is good, and the laboratory examination meets the requirements;
  • Female subjects of reproductive age should agree to use during the study period and for 6 months after the end of the study; Male subjects should agree that contraception must be used during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Have had or are currently suffering from other malignant tumors within 3 years;
  • Have any poorly controlled cardiovascular clinical symptoms or diseases;
  • Patients with ulcerative colitis and Crohn's disease; Patients with active inflammatory bowel disease within the first 4 weeks of enrollment;
  • Symptoms of hematemesis and hematochezia occurred within 6 months before screening, and the daily bleeding volume ≥ 2.5 mL;
  • The presence of unmitigated toxic reactions of grade 1 or above as assessed per (CTC-AE) due to any treatment prior to first administration, excluding hair loss;
  • Patients who had received Programmed Death 1 () or PD-L1 monoclonal antibody treatment and experienced ≥ grade 3 immune-related adverse reactions or stopped immune checkpoint inhibitor treatment due to immune-related adverse reactions;
  • Active or uncontrolled severe infection (≥CTC AE grade 2 infection);
  • Decompensated cirrhosis, active hepatitis;
  • Poor diabetes control (fasting blood glucose > 10 mmol/L);
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia, and require treatment;
  • Had undergone a major surgical, open or significant traumatic injury within 4 weeks prior to the first dose of the study or expected to require major surgery during the study treatment.
  • Patients with arterial/venous thrombosis events, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, occurred within 6 months before the study treatment;
  • Ascites with clinical significance, including any ascites that can be found by physical examination, ascites that have been treated in the past or still need to be treated, and only those who show a small amount of ascites but no symptoms on imaging can be included; Patients with an equal or greater amount of fluid in both pleural cavities, or a large amount of fluid in one pleural cavity, or have caused respiratory dysfunction and need drainage;
  • The presence of unhealed wounds, ulcers or fractures;
  • Have active tuberculosis, or have a history of active tuberculosis infection within 1 year prior to enrollment, or have a history of active tuberculosis infection more than 1 year prior to enrollment, but are not receiving treatment;
  • There is a history of idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia with clinical symptoms, and interstitial lung disease requiring hormone therapy;
  • Have a history of immunodeficiency, including (HIV) positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation or hematopoietic stem cell transplantation;
  • Imaging shows that the tumor has invaded large blood vessels or is not clearly demarcated with blood vessels;
  • Known central nervous system and/or cancerous meningitis;
  • Have multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction);
  • Allergic to the ingredients of the pharmaceutical preparations or , or allergic to similar drugs;
  • An active disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or ) has occurred within 2 years prior to initial medication;
  • Have been diagnosed with immune deficiency or are receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose > 10 mg/day prednisone or other therapeutic hormone) and continue to use within 2 weeks before the first dose;
  • History of vaccination within 28 days before the first dose or planned live attenuated vaccine vaccination during the study period;
  • Have received systematic anti-tumor therapy and other interventional anti-tumor drug clinical trials such as radical surgery, chemotherapy, radical radiotherapy or immunotherapy, biotherapy, etc. within 4 weeks before the start of the study treatment;
  • Within 2 weeks prior to the first drug use, the treatment of Chinese patent drugs with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    TQB2618 injection+Penpulimab injection +Anlotinib hydrochloride capsules

    TQB2618 injection combined with Penpulimab injection and Anlotinib hydrochloride capsules, 3 weeks as a treatment cycle.

    Drug: TQB2618 injection · Drug: Penpulimab injection · Drug: Anlotinib hydrochloride capsules

  • Experimental
    TQB2618 injection+Penpulimab injection

    TQB2618 injection combined with Penpulimab injection, 3 weeks as a treatment cycle.

    Drug: TQB2618 injection · Drug: Penpulimab injection

  • Experimental
    TQB2618 injection

    TQB2618 injection, 3 weeks as a treatment cycle.

    Drug: TQB2618 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    According to RECIST 1.1 or Modified RECIST 1.1 for immune based therapeutics, (iRECIST) criteria, the proportion of subjects whose confirmed tumor volume reduction reached the pre-specified value and maintained the minimum time-frame requirements, i.e., the proportion of subjects with complete response (CR) and partial response (PR).

    Time frame: From first administration until disease progression or withdrawal due to other reasons, estimated to not exceed 8 months.

Secondary outcomes

  1. Overall survival (OS)

    The time from randomization to death from any cause.

    Time frame: Baseline up to death, estimated to not exceed 12 months

  2. Progress free survival (PFS)

    The time from randomization to the first disease progression or death from any cause, whichever occurs first.

    Time frame: From randomization to the time of disease progression or death from any cause, estimated to not exceed 12 months.

  3. Disease control rate (DCR)

    Percentage of subjects with complete response, partial response, or stable disease as determined by RECIST 1.1 or iRECIST.

    Time frame: From first administration to the time of disease progression or withdrawal from any cause, estimated to not exceed 12 months.

  4. Duration of response (DOR)

    From the time the tumor first assessed as complete or partial response to the time of first disease progression or death from any causes.

    Time frame: From first administration to the time of disease progression or death from any cause, estimated to not exceed 12 months.

  5. The incidence of adverse event (AE)

    The incidence and severity of adverse events as determined by the Common Terminology Criteria for Adverse Events (CTC AE).

    Time frame: From first administration to 28 days after withdrawal or the start time of the new anti-tumor treatment, whichever comes first.

  6. Anti-drug antibodies (ADA)

    The occurrence of ADA

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, 30 days and 90 days after the last dose. Each cycle is 21 days.

  7. Neutralizing antibodies (NaB)

    The occurrence of neutralizing antibodies

    Time frame: Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, 30 days and 90 days after the last dose. Each cycle is 21 days.

07

Study locations

4 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2025, 14 months after the start.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's planned 14 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 25, 2023
StartActual
Jan 13, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Jul 2025
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06010901
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Jan 13, 2024
Primary completion
Mar 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Jan 23, 2024

Study contacts

Ruihua Xu, Doctor
Contact
13247323687@163.com
+86 13922206676

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TIM-3 Monoclonal Antibody TQB2618

Start the discussion